HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma

Blood

Volumn 95, Issue 4, 2000, Pages 1406-1412

  Dupin, Nicolas ^b   Diss, Tim L ^b   Kellam, Paul ^b   Tulliez, Micheline ^b   Du, Ming Qing ^b   Sicard, Didier ^b   Weiss, Robin A ^b   Isaacson, Peter G ^a   Boshoff, Chris ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN LAMBDA CHAIN;

ADULT; AGED; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN TISSUE; LYMPHOMA; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS CARCINOGENESIS;

EID: 0034651687     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.4.1406.004k26_1406_1412     Document Type: Article

References (47)

1. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266:1865-1869.
2. Ganem D. KSHV and Kaposi's sarcoma: the end of the beginning. Cell. 1997;91:157-160.
3. Gallo RC. The enigmas of Kaposi's sarcoma. Science. 1998;282:1837-1839.
4. Boshoff C. Kaposi's sarcoma-associated herpesvirus. Cancer Surveys. 1999;157-190.
5. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus/Human Herpesvirus 8. Lyon, France: International Agency for Research on Cancer; 1997. Monographs on the Evaluation of Carcinogenic Risks to Humans, vol 70.
6. Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med. 1998;338:948-954.
7. Sitas F, Carrara H, Beral V, et al. Antibodies against human herpesvirus-8 in black South African patients with cancer. N Engl J Med. 1999; 340:1863-1871.
8. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332:1186-1191.
9. Said W, Chien K, Takeuchi S, et al. Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells. Blood. 1996;7:4937-4943.
10. Jaffe ES. Primary body cavity-based AIDS-related lymphomas. Am J Pathol. 1996;105:141-143.
11. Boshoff C, Gao S-J, Healy LE, et al. Establishment of a KSHV positive cell line (BCP-1) from peripheral blood and characterizing its growth in vivo. Blood. 1998;91:1671-1679.
12. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease Blood. 1995;86:1276-1280.
13. Barozzi P, Luppi M, Masini L, et al. Lymphotropic herpesvirus (EBV, HHV-6, HHV-B) DNA sequences in HIV negative Castleman's disease. J Clin Pathol Mol Pathol. 1996;49:M232-M235.
14. Corbellino M, Poirel L, Aubin JT, et al. The role of human herpesvirus 8 and Epstein-Barr virus in the pathogenesis of giant lymph node hyperplasia (Castleman's disease). Clin Infect Dis. 1996;22: 1120-1121.
15. Gessain A, Sudaka A, Briere J, et al. Kaposi sarcoma-associated herpes-like virus (human herpesvirus type 8) DNA sequences in multicentric Castleman's disease: is there any relevant association in non-human immunodeficiency virus-infected patients? Blood. 1996;87:414-416.
16. Chadburn A, Cesarman E, Nador RG, Liu YF, Knowles DM. Kaposi's sarcoma-associated herpesvirus sequences in benign lymphoid proliferations not associated with human immunodeficiency virus. Cancer. 1997;80:788-797.
17. Parravicini C, Corbellino M, Paulli M, et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV seronegative Castleman's disease. Am J Pathol. 1998;6:1517-1522.
18. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph-node hyperplasia resembling lhymoma. Cancer. 1956;9:822-830.
19. Keller AR, Hochholzer L, Castleman B. Hyalinevascular and plasma cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer, 1972;29:670-683.
20. Frizzera G, Massarelli G, Banks PM, Rosai J. A systemic lymphoproliferative disorder with morphologic features of Castleman s disease. Am J Surg Pathol. 1983;7:211-231.
21. Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H. Multicentric angiofollicutar lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol. 1985;16:162-172.
22. Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman's disease. Ann Intern Med. 1998;128:657-662.
23. Browne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer. 1999;85:706-717.
24. Frizzera G. Castleman's disease and related disorders. Semin Diagn Pathol. 1988;5:346-364.
25. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10:61-67.
26. Abdel-Reheim FA, Koss W, Rappaport ES, Arber DA. Coexistence of Hodgkin's disease and giant lymph node hyperplasia of the plasma-cell type (Castleman's disease). Arch Pathol Lab Med. 1996;91-96.
27. Gould SJ, Diss T, Isaacson PG. Multicentric Castleman's disease in association with a solitary plasmacytoma: a case report. Histopathology. 1990;17:135-140.
28. Hall PA, Donaghy M, Cotter FE, Stansfeld AG, Levison DA. An immunohistological and genotypic study of plasma cell form of Castleman's disease. Histopathology. 1989;14:333-346.
29. Dupin N, Fisher C, Kellam P, et al. Distribution of HHV-8 positive cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A. 1999;96: 4546-4551.
30. Kellam P, Bourboulia D, Dupin N, et al. Characterising monoclonal antibodies against KSHV latent nuclear antigen (LNA-1). J Virol. 1999;73: 5149-5155.
31. Brousset P, Meggetto F, Chirtal S, et al. Methods in laboratory investigation: assessment of the methods for the detection of Epstein-Barr virus nucleic acids and related gene products in Hodgkin's disease. Lab Invest. 1993;69:483-490.
32. Boshoff C, Talbot S, Kennedy M, O'Leary J, Schulz T, Chang Y. HHV8 and skin cancers in immunosuppressed patients [published correction appears in Lancet 1996;348:138]. Lancet. 1996; 347:338-339.
33. Telenti A, Marshall WF, Smith TF. Detection of Epstein-Barr virus by polymerase chain reaction. J Clin Microbiol. 1990;28:2187-2190.
34. Pan LX, Diss TC, Peng HZ, Isaacson PG. Clonality analysis of defined B-cell populations in archival tissue sections using microdissection and polymerase chain reaction. Histopathology. 1994; 24:323-327.
35. Diss TC, Pan L, Peng H, Wotherspoon AC, Isaacson PG. Sources of DNA for detecting B cell monoclonality using PCR. J Clin Pathol. 1994;47: 493-496.
36. Ballestas ME, Chatis PA, Kaye KM. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science. 1999;284:641-644.
37. Miller RT, Mukai K, Banks PM, Frizzera G. Systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Arch Pathol Lab Med. 1984;108:626-630.
38. Radaszkiewicz T, Hansmann ML, Lennert K. Monoclonality and polyclonality of plasma cells in Castleman's disease of the plasma cell variant. Histopathology. 1989;14:11-24.
39. Chilosi M, Menestrina F, Lestani M, et al. Hyaline-vascular type of Castleman's disease (angiofollicular lymph node hyperplasia) with monotypic plasma cells; an immunohistochemical study with monoclonal antibodies. Histol Histopathol 1987; 2:49-55.
40. Matolcsy A, Nador RG, Cesarman E, Knowles DM. Immunoglobulin Vh gene mutational analysis suggests that primary effusion lymphomas derive from different stages of B cell maturation. Am J Pathol. 1998;153:1609-1614.
41. Staskus KA, Sun R, Miller G, et al Cellular tropism and viral interleukin-6 expresion distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. J Virol. 1999;73: 4181-4187.
42. Sarid R, Flore O, Bohenzky RA, Chang Y, Moore PS. Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol. 1998;72:1005-1012.
43. Jacobson LP, Yamashita TE, Detels R, et al. Impact of potent anti-retroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1 infected individuals. J AIDS Retrovirol. In press.
44. Dupin N, Krivine A, Calvez V, Gorin I, Franck N, Escande J-P. No effect of protease inhibitor on clinical and virological evolution of Castleman's disease in an HIV-1 infected patient. AIDS. 1997; 11:1400-1401.
45. Zietz C, Bogner JR, Goebel F-D, Lohrs U. An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS. N Engl J Med. 1999;340:1923-1924.
46. Morassut S, Vaccher E, Balestreri L, et al. HIV-associated human herpesvirus 8-positive primary lymphomatous effusions: radiologic findings in six patients. Radiology. 1997;205:459-463.
47. Nador RG, Cesarman E, Chadbum A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood. 1996;88:645-56.